Search Results

You are looking at 241 - 250 of 1,273 items for :

  • Refine by Access: All x
Clear All
Full access

Stefanie L. Thorsness, Azael Freites-Martinez, Michael A. Marchetti, Cristian Navarrete-Dechent, Mario E. Lacouture, and Emily S. Tonorezos

size or aggressive histologic subtype. Surgery is recommended for primary BCCs and SCCs, but the recommended surgical approaches differ according to risk category. 20 , 21 We aimed to characterize the clinical features, histology, management, and

Full access

Heidi Ko, Yaser Baghdadi, Charito Love, and Joseph A. Sparano

advanced disease; it results in the downstaging of breast and regional nodal disease burden and facilitates breast conservation and/or less extensive axillary surgery. 2 Upstaging to a higher regional stage or detection of metastatic disease may impact

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the health care team may be needed for effective patient care and education. This report summarizes presentations

Full access

Robert W. Carlson, Elizabeth Brown, Harold J. Burstein, William J. Gradishar, Clifford A. Hudis, Charles Loprinzi, Eleftherios Paul Mamounas, Edith A. Perez, Kathleen Pritchard, Peter Ravdin, Abram Recht, George Somlo, Richard L. Theriault, Eric P. Winer, Antonio C. Wolff, and for the NCCN Adjuvant Therapy for Breast Cancer Task Force

persists despite adjuvant therapy in many patients with breast cancer for up to 4 years after surgery. 14 Reports on the prognostic value of minimal residual disease detection show conflicting results. In a systematic review of published studies, minimal

Full access

Lina Jansen, Daniel Boakye, Elizabeth Alwers, Prudence R. Carr, Christoph Reissfelder, Martin Schneider, Uwe M. Martens, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner

characteristics (Charlson comorbidity score and regular use of statins and nonsteroidal anti‐inflammatory drugs [NSAIDs], including aspirin), tumor-related characteristics (year of diagnosis, cancer stage, and cancer site), and treatment characteristics (surgery

Full access

Héctor G. van den Boorn, Ameen Abu-Hanna, Nadia Haj Mohammad, Maarten C.C.M. Hulshof, Suzanne S. Gisbertz, Bastiaan R. Klarenbeek, Marije Slingerland, Laurens V. Beerepoot, Tom Rozema, Mirjam A.G. Sprangers, Rob H.A. Verhoeven, Martijn G.H. van Oijen, Koos H. Zwinderman, and Hanneke W.M. van Laarhoven

cancer can be treated with surgery with or without (neo)adjuvant chemo(radio)therapy. Potentially curable esophageal cancer can also be treated with definitive chemoradiotherapy. Metastatic disease is treated mainly with systemic therapy but also with

Full access

Hiram S. Cody III and Kimberly J. Van Zee

III trial 10853 . Lancet 2000 ; 355 : 528 – 533 . 21 Kestin LL Goldstein NS Martinez AA . Mammographically detected ductal carcinoma in situ treated with conservative surgery with or without radiation therapy: Patterns of failure and 10

Full access

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

distant metastatic site was seen. The patient received adjuvant concurrent chemotherapy and radiation with 6 cycles of weekly intravenous carboplatin (area under the curve, 2) and paclitaxel at 50 mg/m 2 . Four weeks after surgery she received 63 Gy of

Full access

Elisabeth Kenne Sarenmalm, Salmir Nasic, Cecilia Håkanson, Joakim Öhlén, Eva Carlsson, Monica E. Pettersson, and Richard Sawatzky

-14). Sample and Setting The study sample was included in a large person-centered information and communication intervention among patients scheduled for elective CRC surgery. Patients were consecutively enrolled, and data were collected presurgery, including

Full access

Angela K. Green, Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, and Roisin E. O’Cearbhaill

therapy. A small proportion of patients with recurrent ovarian cancer may also be candidates for secondary cytoreductive surgery (SCS) for low-volume, isolated disease, which may be missed without routine surveillance imaging. Recent data suggest that